ADDERALL XR-PARAGRAPH IV NOTICES UPDATE

Shire Pharmaceuticals remains committed to protecting the patents which it has relating to Adderall XR, its product for treatment of attention-deficit/hyperactivity disorder (ADHD). Shire has previously announced a pending suit against Impax Laboratories based on Impax's Paragraph IV notice letter for a 30-mg generic version of Adderall XR. Shire has now filed a second complaint based on an additional Paragraph IV notice letter from Impax advising of the filing of an abbreviated new drug application (ANDA) for a generic version of the 5-mg, 10-mg, 15-mg, 20-mg and 25-mg strengths of Shire's mixed amphetamine product Adderall XR.

BioSpace (http://www.biospace.com/news_story.cfm?StoryID=18705920&full=1)